CCR7

Across TCGA pan-cancer cohorts, CCR7 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of CCR7’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CCR7 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CCR7 is over-expressed in tumor, although a few such as COAD and KICH show the opposite, repressed pattern.

KIRC, COAD, and STAD are the cancer types where CCR7 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CCR7 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+1.187	<.001	11	view →
COAD	All	II,III,IV	−0.770	<.001	7	view →
STAD	Female	All	+2.507	.001	6	view →
KICH	All	II,III,IV	−0.802	.016	4	view →
LUSC	All	All	−0.721	<.001	4	view →
BRCA	All	All	+0.692	<.001	4	view →
ESCA	All	All	+1.529	.006	2	view →
CHOL	All	All	+0.870	.046	1	view →
THCA	All	All	−0.647	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

CCR7–KIRC

Open the KIRC breakdown →